Traffic Lights - Latest Updates

Last updated: 19/09/2018

Other updates on this site
Drug Name Classification Clinical Indication Comments
Actipatch® (NEW) Black Joint and muscle pain
ANAKINRA (Kineret®) (UPDATED) Red Periodic fevers and autoinflammatory diseases

Requested for UHL as part of NHS England commissioning policy

BETA-INTERFERON-1a (Avonex®) (NEW) Red Multiple sclerosis in adults

In line with NICE TA 527
Implementation date 27th September 2018

BETA-INTERFERON-1a (Rebif®) (NEW) Red Multiple sclerosis in adults

In line with NICE TA 527
Implementation date 27th September 2018

BETA-INTERFERON-1b (Betaferon®) (NEW) Red Multiple sclerosis in adults

In line with NICE TA 527
Implementation date 27th September 2018

BETA-INTERFERON-1b (Extavia®) (NEW) Red Multiple sclerosis in adults

In line with NICE TA 527
Implementation date 27th September 2018

BICTEGRAVIR, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE (Biktarvy®) (NEW) Black HIV

Not yet reviewed

BIOSIMILAR TRASTUZUMAB (Herzuma®) (NEW) Black Metastatic breast cancer, early breast cancer and metastatic gastric cancer.
BIOSIMILAR TRASTUZUMAB (Ontruzant®) (NEW) Black for HER2 positive metastatic and early stage breast cancer, HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
CABOZANTINIB (Cabometyx®) (NEW) Black Treatment of advanced renal cell carcinoma.
CEFTOBIPROLE (Zevtera®) (NEW) Black For Hospital and community-acquired pneumonia in adults.
CENEGERMIN (Oxervate®) (NEW) Black Neurotrophic keratitis

Not recommended in NICE TA 532

CIPROFLOXACIN 2mg/ml ear drops (Cetraxal ®) (UPDATED) Green Acute otitis externa

Please see appropriate antimicrobial guidance for treatment advice in otitis externa. Antimicrobial Guidance for Primary Care

DARVADSTROCEL (Alofisel®) (NEW) Black Complex perianal fistulas in adults with Crohn’s disease

Not yet reviewed

DEKAS VITAMINS (various formulations) (NEW) Black Depending on formulation CF, bariatric surgery or liver disease

Not yet reviewed

DOLUTEGRAVIR/RILPIVIRINE (Juluca®) (NEW) Black Adult HIV treatment

Not yet reviewed

DONEPEZIL (UPDATED) Amber Simple Alzheimer's disease

In line with NICE NG 97

Change in traffic light status from 1st October 2018.

DOXEPIN oral (NEW) Red Urticaria paediatrics

Unlicensed

DUPILUMAB (NEW) Red Moderate to severe atopic dermatitis

In line with NICE TA 534

FENTANYL BUCCAL Tablets (Effentora buccal®) (NEW) Black Breakthrough pain for patients with cancer

Not yet reviewed

FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) (UPDATED) Green Rhinitis

To be used in line with the Allergic Rhinitis Pathway

GLATIRAMER ACETATE (Copaxone®) (NEW) Red Multiple sclerosis in adults

In line with NICE TA 527
Implementation date 27th September 2018

GUSELKUMAB (UPDATED) Red Moderate to severe plaque psoriasis in adults

In line with NICE TA 521.

 

IBANDRONIC ACID 50mg tablets (NEW) Amber Simple Prevention of mestastases in early breast cancer patients with low female sex hormones

First three months of prescribing due to renal monitoring to be from the hospital. Stop date to be recorded as total treatment with bisphosphonate to be 36 months. Unlicensed use see NICE ES 15 for more information.

INTERFERON GAMMA (Immukin®) (NEW) Red For mycobacterial infections and pulmonary and miliary
LOMITAPIDE (Lojuxta®) (UPDATED) Red Homozygous familial hypercholesterolaemia

Requested for UHL as part of NHS England commissioning policy.

MEMANTINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

PITOLISANT (Wakix®) (NEW) Amber Simple Narcolepsy
PLASMA-LYTE 148 & 5% GLUCOSE solution for infusion (NEW) Red Source of water, electrolyte and calories or as a alkalinising agent
RALOXIFENE (NEW) Amber Simple Off label chemoprevention to reduce incidence of breast cancer.

Use in line with NICE CG 164

RALOXIFENE (NEW) Black Primary prevention of osteoporotic fragility in menopausal women

Not recommended in NICE TA 160

RALOXIFENE (NEW) Amber Simple Secondary prevention of osteoporotic fragility in menopausal women

In line with NICE TA 161

RIVASTIGMINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

SAFINAMIDE (Xadago®) (UPDATED) Amber Simple Parkinson’s Disease
TERIPARATIDE (UPDATED) Red Osteoporosis in men and women
TOCILIZUMAB (NEW) Red Adult onset stills disease

Requested for UHL as part of NHS England commissioning policy.

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more